Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
